Tags

Type your tag names separated by a space and hit enter

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Adv Ther. 2008 Dec; 25(12):1288-302.AT

Abstract

INTRODUCTION

Patients with stage 2 hypertension require large absolute reductions in blood pressure (BP) to achieve recommended BP goals. Combination therapy with the direct renin inhibitor, aliskiren, and the angiotensin receptor blocker, valsartan, has been shown to produce greater BP reductions than either agent alone in a double-blind study in 1797 hypertensive patients.

METHODS

This post-hoc analysis evaluated the BP-lowering efficacy of aliskiren in combination with valsartan in a subset of patients (n=581) with stage 2 hypertension (baseline mean sitting systolic BP [msSBP] > or =160 mmHg). Patients were randomized to receive aliskiren/valsartan 150/160 mg, aliskiren 150 mg, valsartan 160 mg, or placebo once daily for 4 weeks followed by 4 weeks at double the initial dose. Mean changes from baseline in msSBP and mean sitting diastolic BP were assessed at week-8 endpoint (intent-to-treat population).

RESULTS

Aliskiren/valsartan 300/320 mg reduced BP from baseline by 22.5/11.4 mmHg at week-8 endpoint. BP reductions with combination therapy were significantly greater than with aliskiren 300 mg (17.3/8.9 mmHg, P<0.05), valsartan 320 mg (15.5/8.3 mmHg, P<0.01), or with placebo (7.9/3.7 mmHg, P<0.0001). BP control rates (<140/90 mmHg) were also significantly higher (P<0.05) with aliskiren/valsartan 300/320 mg (29.8%) compared with either aliskiren 300 mg (19.0%) or valsartan 320 mg (13.8%) monotherapy, or placebo (8.9%). All treatments were generally well tolerated.

CONCLUSION

Combination therapy with aliskiren and valsartan provided significantly greater BP reductions over aliskiren or valsartan monotherapy and is an appropriate option for management of BP in patients with stage 2 hypertension.

Authors+Show Affiliations

Chelsea Internal Medicine/IHA, Chelsea, Michigan, USA. steven_yarows@ihacares.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19066757

Citation

Yarows, Steven A., et al. "Aliskiren and Valsartan in Stage 2 Hypertension: Subgroup Analysis of a Randomized, Double-blind Study." Advances in Therapy, vol. 25, no. 12, 2008, pp. 1288-302.
Yarows SA, Oparil S, Patel S, et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther. 2008;25(12):1288-302.
Yarows, S. A., Oparil, S., Patel, S., Fang, H., & Zhang, J. (2008). Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Advances in Therapy, 25(12), 1288-302. https://doi.org/10.1007/s12325-008-0123-x
Yarows SA, et al. Aliskiren and Valsartan in Stage 2 Hypertension: Subgroup Analysis of a Randomized, Double-blind Study. Adv Ther. 2008;25(12):1288-302. PubMed PMID: 19066757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. AU - Yarows,Steven A, AU - Oparil,Suzanne, AU - Patel,Samir, AU - Fang,Hui, AU - Zhang,Jack, PY - 2008/12/11/pubmed PY - 2009/12/17/medline PY - 2008/12/11/entrez SP - 1288 EP - 302 JF - Advances in therapy JO - Adv Ther VL - 25 IS - 12 N2 - INTRODUCTION: Patients with stage 2 hypertension require large absolute reductions in blood pressure (BP) to achieve recommended BP goals. Combination therapy with the direct renin inhibitor, aliskiren, and the angiotensin receptor blocker, valsartan, has been shown to produce greater BP reductions than either agent alone in a double-blind study in 1797 hypertensive patients. METHODS: This post-hoc analysis evaluated the BP-lowering efficacy of aliskiren in combination with valsartan in a subset of patients (n=581) with stage 2 hypertension (baseline mean sitting systolic BP [msSBP] > or =160 mmHg). Patients were randomized to receive aliskiren/valsartan 150/160 mg, aliskiren 150 mg, valsartan 160 mg, or placebo once daily for 4 weeks followed by 4 weeks at double the initial dose. Mean changes from baseline in msSBP and mean sitting diastolic BP were assessed at week-8 endpoint (intent-to-treat population). RESULTS: Aliskiren/valsartan 300/320 mg reduced BP from baseline by 22.5/11.4 mmHg at week-8 endpoint. BP reductions with combination therapy were significantly greater than with aliskiren 300 mg (17.3/8.9 mmHg, P<0.05), valsartan 320 mg (15.5/8.3 mmHg, P<0.01), or with placebo (7.9/3.7 mmHg, P<0.0001). BP control rates (<140/90 mmHg) were also significantly higher (P<0.05) with aliskiren/valsartan 300/320 mg (29.8%) compared with either aliskiren 300 mg (19.0%) or valsartan 320 mg (13.8%) monotherapy, or placebo (8.9%). All treatments were generally well tolerated. CONCLUSION: Combination therapy with aliskiren and valsartan provided significantly greater BP reductions over aliskiren or valsartan monotherapy and is an appropriate option for management of BP in patients with stage 2 hypertension. SN - 0741-238X UR - https://www.unboundmedicine.com/medline/citation/19066757/Aliskiren_and_valsartan_in_stage_2_hypertension:_subgroup_analysis_of_a_randomized_double_blind_study_ L2 - https://dx.doi.org/10.1007/s12325-008-0123-x DB - PRIME DP - Unbound Medicine ER -